TrialCancer discovery2020

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.

Jennifer A Woyach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.